PKB/Akt | QF-Pro Glossary

View

Definition

Akt/PKB is the central effector of PI3K pathway signaling, activated by phosphorylation at T308 (PDK1) and S473 (mTORC2). aFRET-based detection of Akt activation in breast cancer and renal cell carcinoma demonstrated that activation state predicts patient survival–while Akt expression by conventional IHC showed no prognostic value.

Video Segments

Post-Translational Modifications via aFRET

Primary

Activation = function

Phosphorylation state matters

FRET predicts survival

2.5%–6.0% efficiency range

Expression fails

IHC intensity no correlation

Pathway convergence

Central signaling node

The Canonical Oncoprotein

Akt/PKB occupies a central position in oncogenic signaling. It lies at the convergence of multiple upstream inputs–receptor tyrosine kinases (HER2, EGFRLoading..., IGF-1R), PI3K activation, and PTENLoading... loss–and controls diverse downstream functions including cell proliferation, survival, metabolism, and migration.

Akt activation requires two phosphorylation events: T308 (by PDK1) and S473 (by mTORC2). These phosphorylation events induce conformational changes that expose the kinase active site and enable substrate phosphorylation.

Because Akt integrates multiple oncogenic signals and controls critical cellular decisions, its activation state–not merely its expression–reflects the functional biology of the tumor.

Simplified

Central Hub: Akt (also called PKB) receives signals from multiple sources (growth factor receptors, PI3K) and controls cell survival, growth, and metabolism. It's overactive in many cancers.

Activation Mechanism: Akt activation requires phosphorylation at specific sites (T308 and S473), which cause conformational changes that activate its kinase function.

Activation vs Expression: The 2014 Evidence

The distinction between activation and expression was definitively demonstrated in breast cancer studies published in 2014.

Expression-based analysis (IHC): Total Akt protein levels showed no correlation with patient outcomes. Intensity ratios failed to stratify patients into prognostic groups. Expression told clinicians nothing about prognosis.

Activation-based analysis (aFRET): Akt activation measured by fretLoading...-efficiency|FRET efficiency}} (range 2.5%–6.0%) significantly predicted both disease-free and overall survival. High activation identified patients with worse prognosis.

This represents a paradigm case for functional biomarkersLoading...: the same protein, measured two different ways, yields completely different clinical utilityLoading.... Expression measures abundance. FRET measures function. Function predicts outcomes.

Simplified

The Landmark Finding: In 164 breast cancer patients:

• Akt ACTIVATION (FRET): Predicted both disease-free and overall survival

• Akt EXPRESSION (IHC): Predicted nothing

This proved that activation state provides clinically meaningful information that expression cannot—the foundation of the functional biomarker paradigm.

QF-Pro Application

Clinically Validated

Clinical Validation: PKB/Akt represents a paradigm-defining application demonstrating that activation state predicts outcomes where expression fails.

In breast cancer (2014), amplified FRET measurement of Akt activation in tissue microarrays from 164 patients showed that high activation significantly predicted reduced disease-free survival (P=0.036^[1]) and overall survival (P=0.013^[1]). IHC-based expression showed no prognostic correlation (P=0.890 for DFS, P=0.746 for OS).

In clear cell RCC (2017): Akt activation correlated with poor survival (HR 0.228^[2], P=0.002^[2]) while phospho-Akt expression by IHC failed (P=0.548).

Click citation numbers to view full references in QF-Pro Applications & Clinical EvidenceLoading...

Simplified

What this means: Akt activation state (measured by FRET) predicts patient survival in both breast cancer and kidney cancer. Traditional expression testing showed no correlation at all. This established the core principle: function predicts outcomes, expression doesn't.

Akt Expression (IHC)

Protein abundance measurement
No survival correlation (p>0.05)
"Is it present?"

Akt Activation (aFRET)

Functional state measurement
Predicts DFS and OS (p<0.05)
"Is it working?"

Clinical Evidence

Breast cancerLoading... (2014): aFRETLoading...-measured Akt activation (efficiency range 2.5%–6.0%) predicted disease-free and overall survival; IHCLoading...-measured expression showed no prognostic value
Renal cell carcinoma: Akt activation correlated with worsened patient outcome, confirming the functional biomarkerLoading... paradigm in a second malignancy
Two-site detection: aFRETLoading... measures the conformational change associated with activation–a functional readout impossible with single-antibody expression assays
Pathway integration: Akt activation reflects upstream PI3K/PTEN status and predicts response to PI3K pathway inhibitors

Connected Terms

aFRET Cross-ref Related Simulation Video
EGFR Category Cross-ref Related Learning Path
Functional Biomarkers Cross-ref Related Simulation Video
HER2-HER3 Dimerization Category Related Learning Path
PTEN Category Cross-ref Related
Breast Cancer Cross-ref Related
FRET Cross-ref Related
mTOR Category Cross-ref Related